JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eckardt, L.
Right arrow Articles by Haverkamp, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eckardt, L.
Right arrow Articles by Haverkamp, W.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Vol. 300, Issue 1, 64-71, January 2002

Electrophysiologic Characterization of the Antipsychotic Drug Sertindole in a Rabbit Heart Model of Torsade de Pointes: Low Torsadogenic Potential Despite QT Prolongation

Lars Eckardt, Günter Breithardt and Wilhelm Haverkamp

Hospital of the Westfälische Wilhelms-University, Department of Cardiology and Angiology and Institute for Arteriosclerosis Research, Münster, Germany

There is growing concern that antipsychotic drugs that prolong the QT interval almost always increase the risk for patients to develop life-threatening ventricular tachyarrhythmias (VTs) of the torsade de pointes type. We therefore sought to compare the electrophysiologic effects of the psychotropic agent sertindole, which prolongs cardiac repolarization by inhibiting the rapid component of the delayed rectifier potassium current (IKr) but has a low torsadogenic potential to the antiarrhythmic agent dl-sotalol. In 18 Langendorff-perfused rabbit hearts, sotalol (10 µM, n = 8) and sertindole (0.5, 1.0, and 1.5 µM; n = 10) led to significant and comparable QT prolongation. In the presence of sotalol, torsade de pointes reproducibly occurred in atrioventricular node-blocked hearts after lowering the potassium concentration to 1.5 mM. High doses of sertindole (1.5 µM) only caused monomorphic VT (n = 4) and nonsustained polymorphic VT (n = 2) in the presence of QRS prolongation. Multiple simultaneous epi- and endocardial monophasic action potentials and a volume-conducted ECG demonstrated widening of the T/U wave, early afterdepolarizations, and increased dispersion of repolarization in the presence of dl-sotalol. In contrast to sotalol, QT and monophasic action potential prolongation were cycle length-independent in the presence of sertindole. Sertindole had no significant effect on transmural or interventricular dispersion of repolarization. Early afterdepolarizations did not occur. Despite comparable QT prolongation, sertindole did not display the proarrhythmic profile typical of other blockers of IKr such as dl-sotalol. It is likely that a different mode of interaction between sertindole and the channel and/or additional pharmacological effects of sertindole, e.g., its ability to inhibit INa and/or its ability to block alpha 1-receptors, play a role.


0022-3565/02/3001-0064$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Cardiovasc ResHome page
P. Milberg, N. Reinsch, K. Wasmer, G. Monnig, J. Stypmann, N. Osada, G. Breithardt, W. Haverkamp, and L. Eckardt
Transmural dispersion of repolarization as a key factor of arrhythmogenicity in a novel intact heart model of LQT3
Cardiovasc Res, February 1, 2005; 65(2): 397 - 404.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
A. T. Harvey, D. Flockhart, J. C. Gorski, D. J. Greenblatt, M. Burke, S. Werder, and S. H. Preskorn
Intramuscular Haloperidol or Lorazepam and QT Intervals in Schizophrenia
J. Clin. Pharmacol., October 1, 2004; 44(10): 1173 - 1184.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
C. Antzelevitch, L. Belardinelli, L. Wu, H. Fraser, A. C. Zygmunt, A. Burashnikov, J. M. Di Diego, J. M. Fish, J. M. Cordeiro, R. J. Goodrow Jr, et al.
Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S65 - S83.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. B. Thomsen, P. G. A. Volders, M. Stengl, R. L. H. M. G. Spaatjens, J. D. M. Beekman, U. Bischoff, M. A. Kall, K. Frederiksen, J. Matz, and M. A. Vos
Electrophysiological Safety of Sertindole in Dogs with Normal and Remodeled Hearts
J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 776 - 784.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. Milberg, L. Eckardt, H.-J. Bruns, J. Biertz, S. Ramtin, N. Reinsch, D. Fleischer, P. Kirchhof, L. Fabritz, G. Breithardt, et al.
Divergent Proarrhythmic Potential of Macrolide Antibiotics Despite Similar QT Prolongation: Fast Phase 3 Repolarization Prevents Early Afterdepolarizations and Torsade de Pointes
J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 218 - 225.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.